Luis Pena Sells 7,438 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) CEO Luis Pena sold 7,438 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $22.71, for a total value of $168,916.98. Following the completion of the transaction, the chief executive officer owned 630,458 shares of the company’s stock, valued at $14,317,701.18. This trade represents a 1.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Evommune Stock Performance

Evommune stock opened at $24.00 on Friday. The business’s 50-day simple moving average is $23.02 and its two-hundred day simple moving average is $22.29. The company has a market cap of $864.43 million and a PE ratio of -2.53. Evommune, Inc. has a fifty-two week low of $13.89 and a fifty-two week high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. As a group, analysts predict that Evommune, Inc. will post -2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

EVMN has been the subject of several research reports. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 price objective on shares of Evommune in a research note on Friday, April 10th. Wall Street Zen cut shares of Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Oppenheimer initiated coverage on shares of Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price for the company. Clear Str raised shares of Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Evommune in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $49.25.

Institutional Investors Weigh In On Evommune

Hedge funds and other institutional investors have recently made changes to their positions in the company. Capricorn Fund Managers Ltd purchased a new position in shares of Evommune during the 4th quarter valued at approximately $1,027,000. China Universal Asset Management Co. Ltd. purchased a new stake in Evommune during the fourth quarter worth $34,000. Sectoral Asset Management Inc. acquired a new stake in Evommune during the fourth quarter valued at $10,084,000. Geode Capital Management LLC acquired a new stake in Evommune during the fourth quarter valued at $1,881,000. Finally, Seven Grand Managers LLC purchased a new position in Evommune in the fourth quarter valued at $1,284,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.